Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts

Texto completo
Autor(es):
Mostrar menos -
Rossini, P. M. [1] ; Di Iorio, R. [2] ; Vecchio, F. [3] ; Anfossi, M. [4] ; Babiloni, C. [5, 6, 7] ; Bozzali, M. [8, 9] ; Bruni, A. C. [4] ; Cappa, S. F. [10, 11] ; Escudero, J. [12] ; Fraga, F. J. [13] ; Giannakopoulos, P. [14] ; Guntekin, B. [15, 16] ; Logroscino, G. [17] ; Marra, C. [18] ; Miraglia, F. ; Panza, F. [17] ; Tecchio, F. [3, 19] ; Pascual-Leone, A. [20, 21, 22] ; Dubois, B. [23, 24]
Número total de Autores: 19
Afiliação do(s) autor(es):
Mostrar menos -
[1] IRCCS San Raffaele Pisana, Dept Neurosci & Neurorehabil, Rome - Italy
[2] IRCCS Polyclin A Gemelli Fdn, Area Neurosci, Inst Neurol, Rome - Italy
[3] IRCCS San Raffaele Pisana, Dept Neurosci & Neurorehabil, Brain Connect Lab, Rome - Italy
[4] ASP CZ, Neurogenet Reg Ctr, Lamezia Terme - Italy
[5] Sapienza Univ Rome, Dept Physiol & Pharmacol Erspamer, Rome - Italy
[6] Inst Res & Med Care IRCCS San Raffaele Pisana & C, Rome - Italy
[7] Inst Res & Med Care IRCCS San Raffaele Pisana & C, Cassino - Italy
[8] Univ Sussex, Brighton & Sussex Med Sch, Dept Neurosci, Brighton, E Sussex - England
[9] IRCCS Santa Lucia Fdn, Neuroimaging Lab, Rome - Italy
[10] Inst Adv Studies IUSS, Pavia - Italy
[11] Inst Res & Med Care IRCCS S Giovanni Dio Fatebene, Brescia - Italy
[12] Univ Edinburgh, Inst Digital Commun, Sch Engn, Edinburgh, Midlothian - Scotland
[13] Fed Univ ABC UFABC, Engn Modelling & Appl Social Sci Ctr CECS, Sao Paulo - Brazil
[14] Univ Hosp Geneva, Med Direct, Div Inst Measures, Geneva - Switzerland
[15] Istanbul Medipol Univ, Int Sch Med, Dept Biophys, Istanbul - Turkey
[16] Istanbul Medipol Univ, Clin Electrophys Neuroimaging & Neuromodulat Lab, REMER, Istanbul - Turkey
[17] Univ Bari Aldo Moro, Dept Basic Med, Neurodegenerat Dis Unit, Neurosci & Sense Organs, Bari - Italy
[18] Univ Cattolica Sacro Cuore, Inst Neurol, Rome - Italy
[19] CNR, ISTC Inst Cognit Sci & Technol, LETS Lab Electrophysiol Translat NeuroSci, Rome - Italy
[20] Harvard Med Sch, Dept Neurol, Boston, MA 02115 - USA
[21] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02115 - USA
[22] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Cognit Neurol, Boston, MA 02115 - USA
[23] Hop La Pitie Salpetriere, Dept Neurol, Inst Memoire & Maladie Alzheimer, Paris - France
[24] UPMC Univ Paris 06, Sorbonne Univ, CNRS, INSERM, Inst Cerveau & Moelle ICM, Paris - France
Número total de Afiliações: 24
Tipo de documento: Artigo de Revisão
Fonte: CLINICAL NEUROPHYSIOLOGY; v. 131, n. 6, p. 1287-1310, JUN 2020.
Citações Web of Science: 1
Resumo

Alzheimer's disease (AD) is the most common neurodegenerative disease among the elderly with a progressive decline in cognitive function significantly affecting quality of life. Both the prevalence and emotional and financial burdens of AD on patients, their families, and society are predicted to grow significantly in the near future, due to a prolongation of the lifespan. Several lines of evidence suggest that modifications of risk-enhancing life styles and initiation of pharmacological and nonpharmacological treatments in the early stage of disease, although not able to modify its course, helps to maintain personal autonomy in daily activities and significantly reduces the total costs of disease management. Moreover, many clinical trials with potentially disease-modifying drugs are devoted to prodromal stages of AD. Thus, the identification of markers of conversion from prodromal form to clinically AD may be crucial for developing strategies of early interventions. The current available markers, including volumetric magnetic resonance imaging (MRI), positron emission tomography (PET), and cerebral spinal fluid (CSF) analysis are expensive, poorly available in community health facilities, and relatively invasive. Taking into account its low cost, widespread availability and non-invasiveness, electroencephalography (EEG) would represent a candidate for tracking the prodromal phases of cognitive decline in routine clinical settings eventually in combination with other markers. In this scenario, the present paper provides an overview of epidemiology, genetic risk factors, neuropsychological, fluid and neuroimaging biomarkers in AD and describes the potential role of EEG in AD investigation, trying in particular to point out whether advanced analysis of EEG rhythms exploring brain function has sufficient specificity/sensitiv ity/accuracy for the early diagnosis of AD. (C) 2020 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved. (AU)

Processo FAPESP: 18/03655-1 - Biomarcadores de eletroencefalograma baseados em conectividade cerebral para diagnóstico automatizado da Doença de Alzheimer
Beneficiário:Francisco José Fraga da Silva
Linha de fomento: Bolsas no Exterior - Pesquisa
Processo FAPESP: 17/15243-7 - Análise de Conectividade Cerebral baseada em Eletroencefalografia para Auxílio ao Diagnóstico da Doença de Alzheimer e da Lesão Axonal Difusa
Beneficiário:Francisco José Fraga da Silva
Linha de fomento: Auxílio à Pesquisa - Regular